Nektar Therapeutics  (NKTR) Trade Now »     Rate NKTR  -  Discuss NKTR  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

NKTR: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on NKTR ... NKTR

76%

+9.41% in 2 days (closed on 10/23/08) Just paying for my sins in the energy market. A large portion of Nektar has been purchased by Novartis. Continue reading »

BUY: Nektar Therapeutics (NKTR) NKTR

14%

-26.97% in 1007 days BUY: Nektar Therapeutics (NKTR): $14.01 (1/12/07) Sell price: $15.21 or Sell date: February 12, 2007Trailing stop: $13.25 (-5.4%) Oversold, odds favor long trades.Strong Down trend (1 month), not sustainable, occurs only 15% of the time, expect trend to turn sideways or higher.Analyst sentiment at around $19. Profile: Nektar Therapeutics is a biopharmaceutical company. The Company [...] Continue reading »

From the Blogosphere

Top 40 Rated Emerging Bio-Pharma Stocks

73%

The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return. The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ... Continue reading »

Top 40 Rated Emerging Bio-Pharma Stocks

73%

The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return. The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ... Continue reading »

Pfizer Needs Isis More Than Isis Needs Pfizer

<> In January of 2007, shortly after Isis (ISIS) announced its multibillion dollar, collaboration with Genzyme (GENZ), I chided an executive of Pfizer (PFE), asking how they could let rival Genzyme outbid them for the rights to Mipomersen. He (correctly) pointed out that the mode of delivery was the key factor in their decision. Mipomersen is initially slated to be given by injection (albeit weekly) for Homozygous Familial Hypercholesterolemia, although an oral formulation will probably be available for the larger 1.5 to 2 million heterogeneous and poorly controlled hyperlipidemic patient p... Continue reading »

Unusual 11 Mid-Day Movers 4/9: EPMD, ONCY, SPR, XRM Higher; MNKD, NRGN, NKTR, PTRY Lower

EP MedSystems, Inc. (NASDAQ: EPMD) 102% HIGHER; St. Jude Medical, Inc. (NYSE: STJ) will acquire the company for $3.00 per share. MannKind Corp. (NASDAQ: MNKD) 60.9% LOWER; Warning from Pfizer on inhaled insulin causing lung cancer. Neurogen Corporation (Nasdaq: NRGN) 31.8% LOWER; today announced it has entered into definitive agreements for a private placement offering of exchangeable preferred stock and warrants with selected institutional investors for gross proceeds of approximately $30.6 million before fees and expenses.Nektar Therapeutics (NASDAQ: NKTR) 28.4% LOWER; Ceased all negotiat... Continue reading »

Thursday's Upgrades and Downgrades

2 %

<> Upgrades Wolverine (WWW)- Sterne Agee Hold » Buy Washington Mutual (WM)- DA Davidson Underperform » Neutral Prudential Plc (PUK)- Keefe Bruyette Underperform » Outperform Sealy (ZZ)- Morgan Keegan Mkt Perform » Outperform GrafTech Intl (GTI)- Oppenheimer Perform » Outperform Canadian Natrl Res (CNQ)- Lehman Brothers Equal-weight » Overweight Fairport Comms (FRP)- Soleil Hold » Buy Downgrades Sigma Designs (SIGM)- Collins Stewart Buy » Hold Mannkind (MNKD)- Leerink Swann Outperform » Mkt Perform LifeCell (LIFC)- Roth Capital Buy » Hold Nektar Therape... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.